Melphalan-associated pulmonary toxicity following high-dose therapy with autologous hematopoietic stem cell transplantation

Melphalan can rarely cause interstitial pneumonitis and fibrosis, Although it has been reported previously in patients after conventional doses, we re port four cases developing diffuse interstitial pneumonitis (DIP) after hig h-dose melphalan-based therapy. In a 3-year period, four of 57 (7%) consecu tive patients undergoing high-dose melphalan (200 mg/m(2); MEL 200) were id entified with DIP. Two patients who were heavily pre-treated with alkylator s developed progressive respiratory failure despite high-dose steroids and eventually died. The other two patients previously treated with vincristine , adriamycin, and dexamethasone (VAD) improved dramatically on high-dose st eroids with complete resolution of their pneumonitis. Melphalan should be a dded to the growing list of alkylators causing pulmonary toxicity.